KRAS and non-small cell lung carcinoma: Notwithstanding this, KRAS testing is not included in the routine genomic panel for NSCLC, probably due to its less well-established efficacy in daily clinical practice based on current evidence [The European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of Molecular Targets (ESCAT) recommendation category 2B] [6,7].